At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 40 enrolled
Drug / intervention
E7090drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of E7090 in Subjects With Solid Tumor
In Brief
A Phase 1 clinical trial evaluating E7090 for Tumors. Completed, enrolled 40 participants across 18 sites.
Detailed Summary
This is a Phase 1 study of E7090 in subjects with advanced solid tumors. This study will be conducted in 2 parts: 1. Part 1 will be the dose escalation portion of this study to determine the maximum tolerated dose in subjects with solid tumors, and 2. Part 2 will comprise cohort expansions to further characterize the safety and tolerability of E7090 and to assess preliminary efficacy of E7090 in subjects with solid tumors characterized by genetic abnormalities in FGF/FGFR pathway.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTumors
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartOct 2014
Primary CompletionSep 2021
TodayJul 2026
First PostedOct 27, 2014
Enrollment StartOct 28, 2014
Primary CompletionSep 3, 2021
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 11.7 years ago
Interventions
E7090drug